Update from The Oncology Convention 2020

The organiser of the leading medical show The Oncology Convention (17th-18th March 2020, NEC Birmingham), has been closely monitoring updates on the spread of the COVID-19 Coronavirus.

Like many large event organisers, the health and safety of our visitors, exhibitors and staff is always our number one priority. This is particularly pertinent in the care and health sector communities that The Oncology Convention brings together.

Many of our visitors are, or are on the frontline of supporting, the most vulnerable in society. This combined with the fact that health and social care workers will be critical to ongoing containment and management strategies, means that we have taken the decision to reschedule The Oncology Convention to 9th – 10th November 2020.

While this is not a decision that has been taken lightly, we feel that it is the right one – not just for the care and health sector but for the wider community as a whole. We are of course, in ongoing communication with our exhibitors, speakers, partners and suppliers. Those we have managed to speak to thus far have been exceptionally understanding.

Thank you for your understanding and support and we look forward to welcoming you later in the year.

Latest News

By BOPA Committee on 22nd January 2025

NIHR INSIGHT Programme South London Research Masters Studentships 2025/26: Call for applications

NIHR INSIGHT Programme South London Research Masters Studentships 2025/26: Call for applications is now open. For more info click here and/or see flyer below.  

Read article
By BOPA research committee on 22nd January 2025

SURVEY: Examining barriers to pharmacy professionals engaging with research

The Incubator for Pharmacy Professionals is an NIHR-supported initiative dedicated to strengthening research capacity within the pharmacy profession. Despite its critical role as a pillar of professional practice, research remains…

Read article
By BOPA on 20th January 2025

Monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

The Immune-Related Adverse Effects that arise from use of checkpoint inhibitors can be difficult to manage, especially when steroids are not enough. Despite there being guidance about how to manage…

Read article
By BOPA Committee on 20th January 2025

UTIC course has been awarded a FIP Seal

UTIC (Understanding targeted therapies and immunotherapies for cancer) course has been awarded a FIP Seal. This is a joint collaboration between BOPA and ISOPP. The FIP Seal for programmes is…

Read article